Get the Stockscreener App
302.99
0.50%
-1.52
After Hours:
302.99
Bio Rad Laboratories Inc stock is traded at $302.99, with a volume of 99,629.
It is down -0.50% in the last 24 hours and down -6.73% over the past month.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
See More
Previous Close:
$304.51
Open:
$305.81
24h Volume:
99,629
Relative Volume:
0.51
Market Cap:
$8.17B
Revenue:
$2.58B
Net Income/Loss:
$-778.69M
P/E Ratio:
-11.09
EPS:
-27.33
Net Cash Flow:
$223.75M
1W Performance:
+0.41%
1M Performance:
-6.73%
6M Performance:
+25.56%
1Y Performance:
-7.77%
1-Day Range:
$300.26
$305.98
1-Week Range:
$300.26
$305.98
52-Week Range:
$211.43
$373.69
Bio Rad Laboratories Inc Stock (BIO) Company Profile
Name
Bio Rad Laboratories Inc
Sector
Industry
Phone
(510) 724-7000
Address
1000 ALFRED NOBEL DRIVE, HERCULES
Compare BIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIO
Bio Rad Laboratories Inc
|
302.99 | 8.21B | 2.58B | -778.69M | 223.75M | -27.33 |
|
ABT
Abbott Laboratories
|
125.29 | 218.72B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
95.35 | 142.33B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
351.47 | 135.42B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
96.06 | 123.92B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
85.25 | 50.02B | 5.88B | 1.34B | 799.60M | 2.3489 |
Bio Rad Laboratories Inc Stock (BIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-01-24 | Upgrade | Citigroup | Neutral → Buy |
| Aug-28-24 | Initiated | Wells Fargo | Equal Weight |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Apr-03-24 | Downgrade | Citigroup | Buy → Neutral |
| Dec-07-23 | Initiated | UBS | Buy |
| Jun-16-23 | Initiated | Wells Fargo | Overweight |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jan-28-22 | Reiterated | Citigroup | Buy |
| Jan-08-20 | Initiated | Wells Fargo | Overweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Oct-17-18 | Initiated | Goldman | Buy |
| Sep-20-18 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-16-18 | Downgrade | CL King | Buy → Neutral |
| Jul-13-17 | Initiated | Wells Fargo | Outperform |
| Jun-28-17 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-18-17 | Initiated | Deutsche Bank | Hold |
| Oct-13-16 | Initiated | CL King | Buy |
| May-06-15 | Reiterated | Jefferies | Buy |
| Dec-18-09 | Initiated | Maxim Group | Buy |
| Nov-06-09 | Initiated | Jefferies & Co | Buy |
| Jul-17-09 | Initiated | Soleil | Buy |
| Sep-26-07 | Initiated | Banc of America Sec | Buy |
| Feb-23-07 | Downgrade | Robert W. Baird | Outperform → Neutral |
View All
Bio Rad Laboratories Inc Stock (BIO) Latest News
Bio-Rad Laboratories, Inc. (NYSE:BIO) Receives Average Rating of "Hold" from Brokerages - MarketBeat
Helicobacter Pylori Diagnostics Market Forecast Through - openPR.com
Sample Preparation Market 2025 Forecast: In-Depth Industry - openPR.com
Boston Trust Walden Corp Invests $26.76 Million in Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Responsive Playbooks and the BIO Inflection - Stock Traders Daily
Marathon Asset Management Ltd Sells 7,893 Shares of Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Protein A Resin Market is expected to reach US$ 4.1 billion by 2032 - openPR.com
Newborn Screening Market Assessment 2032: Segment Analysis, - openPR.com
Japan's Life Sciences Research and Clinical Applications Fuel - openPR.com
BIO (Bio-Rad Laboratories) Sale Of Property, Plant, Equipme - GuruFocus
Harbor Capital Advisors Inc. Lowers Stock Holdings in Bio-Rad Laboratories, Inc. $BIO - MarketBeat
United states DNA Forensics Market to Reach USD 5.60 Billion - openPR.com
United states IVD Quality Control Market expected to grow at - openPR.com
United states Molecular Quality Controls Market expected - openPR.com
Bio-Rad Laboratories Earnings Notes - Trefis
Robust Growth in Molecular Quality Control Market (2025-2032): - openPR.com
Exchange Traded Concepts LLC Buys 7,648 Shares of Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Life Science Instruments & Consumables Market to Reach USD - openPR.com
Enzyme-Linked Immunosorbent Assay Market is expected to reach - openPR.com
BIO (Bio-Rad Laboratories) EV-to-OCF : 16.80 (As of Dec. 23, 2025) - GuruFocus
Bio-Rad Laboratories, Inc. Class A Common Stock (NY: BIO - FinancialContent
Cell Viability Assays Market Soars as Drug Discovery Demand - openPR.com
Why Bio Rad Laboratories Inc. stock attracts global investorsTrade Risk Assessment & Capital Protection Trading Alerts - Улправда
Published on: 2025-12-20 23:30:31 - Улправда
Can Bio Rad Laboratories Inc. (BUW) stock sustain margin levelsJuly 2025 PostEarnings & Risk Managed Trade Strategies - bolumsonucanavari.com
How Bio Rad Laboratories Inc. stock performs in interest rate cycles2025 Top Decliners & Capital Efficient Trading Techniques - Улправда
Published on: 2025-12-20 08:31:22 - Улправда
Will Bio Rad Laboratories Inc. stock recover faster than marketMarket Sentiment Review & Safe Entry Point Identification - Улправда
Is Bio Rad Laboratories Inc. stock resilient to inflationJuly 2025 Institutional & High Accuracy Swing Entry Alerts - ulpravda.ru
Why Bio Rad Laboratories Inc. stock is trending among retail tradersJuly 2025 Snapshot & Capital Efficient Trade Techniques - Bölüm Sonu Canavarı
Why Bio Rad Laboratories Inc. stock is rated strong buy2025 Biggest Moves & Weekly Return Optimization Plans - ulpravda.ru
Why Bio Rad Laboratories Inc. (BUW) stock is a must watch tickerMarket Sentiment Report & Real-Time Buy Zone Alerts - DonanımHaber
Is Bio Rad Laboratories Inc. stock a smart buy before Fed meetingJuly 2025 Retail & Entry Point Confirmation Alerts - DonanımHaber
Published on: 2025-12-19 13:52:52 - DonanımHaber
Is Bio Rad Laboratories Inc. stock in correction or buying zone2025 Performance Recap & Low Drawdown Momentum Trade Ideas - DonanımHaber
Liquidity Mapping Around (BIO) Price Events - Stock Traders Daily
Loss Report: Is Bio Rad Laboratories Inc. Class B stock worth buying before Fed action - Улправда
Guidance Update: Will Bio Rad Laboratories Inc. stock gain from government policies2025 Fundamental Recap & AI Powered Buy and Sell Recommendations - Улправда
Bio-Rad Laboratories (FRA:BUWA) EV-to-FCF : 22.87 (As of Dec. 18, 2025) - GuruFocus
Assessment of InteliQ Multiqual Tube-Based QC Materials - Labroots
Bio-Rad Fails in Bid to Exclude Internal Communications in Ex-GC's Whistleblower Suit - Law.com
In Vitro Toxicity Testing Market Set for Dynamic Growth with Key - openPR.com
Published on: 2025-12-18 13:31:33 - Улправда
Is Bio Rad Laboratories Inc. stock a safe investment in uncertain marketsJuly 2025 Rallies & Risk Controlled Daily Plans - Улправда
Bio-Rad Laboratories Mourns Loss of Co-Founder Alice Schwartz - MSN
Published on: 2025-12-18 04:48:11 - moha.gov.vn
Multi Omics Platform Market Outlook 2025-2032: Key Trends, Size - openPR.com
Nucleic Acid Extraction Equipment Market Analysis Report 2025-2034 - Insightace Analytic
Establishing Best Practices in Quality Control Management - Labroots
DNA/RNA Extraction Kit Market to Reach US$ 5.12 Billion by 2033 - openPR.com
Fragment Analysis Market 2025-2032: Growth Overview, Facts & - openPR.com
Bio Rad Laboratories Inc Stock (BIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.97%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):